Adverum Biotechnologies, Inc. (ADVM)

Market Cap	94.64M
Revenue (ttm)	1,000,000
Net Income (ttm)	-169.49M
Shares Out	20.98M
EPS (ttm)	-8.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	456,633
Open	4.190
Previous Close	4.310
Day's Range	4.020 - 4.540
52-Week Range	1.780 - 8.560
Beta	0.92
Analysts	Strong Buy
Price Target	19.75 (+337.92%)
Earnings Date	Nov 3, 2025

About ADVM

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal co...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 31, 2014
• Employees: 155
• Stock Exchange: NASDAQ
• Ticker Symbol: ADVM
• Website: https://adverum.com

Financial Performance

In 2024, Adverum Biotechnologies's revenue was $1.00 million, a decrease of -72.22% compared to the previous year's $3.60 million. Losses were -$130.93 million, 7.22% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for ADVM stock is "Strong Buy." The 12-month stock price target is $19.75, which is an increase of 337.92% from the latest price.

Price Target

$19.75

(337.92% upside)

Analyst Consensus: Strong Buy